The San Diego biotech is also de-emphasizing three ongoing targeted cancer therapy candidates and giving itself the flexibility to focus on RAS- or KRAS-targeting approaches.

NeuroSense plans to adjust its upcoming clinical trial to avoid the fate of Amylyx’s ALS candidate, which was recently withdrawn from the market due to a lack of efficacy.

Rahul Rao, the deputy director of the FTC Bureau of Competition, discussed the agency’s thinking on recent pharma deals that it viewed as anti-competitive.

The UK major’s head of respiratory and immunology, Pablo Panella, tells Scrip that AstraZeneca’s well established presence in the field “gives us an edge.”